{"id":36697,"date":"2025-07-04T16:30:11","date_gmt":"2025-07-04T08:30:11","guid":{"rendered":"https:\/\/flcube.com\/?p=36697"},"modified":"2025-07-04T16:30:11","modified_gmt":"2025-07-04T08:30:11","slug":"bioversys-partners-with-shionogi-to-advance-bv500-for-non-tuberculous-mycobacterial-infections","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36697","title":{"rendered":"BioVersys Partners with Shionogi to Advance BV500 for Non-Tuberculous Mycobacterial Infections"},"content":{"rendered":"\n

Swiss biopharma BioVersys AG (SWX: BIOV<\/a>) announced a research and exclusive license option agreement with Japan-based Shionogi & Co., Ltd. (TYO: 4507<\/a>) to jointly advance novel ansamycin-class molecules for treating non-tuberculous mycobacterial (NTM) infections. The collaboration is based on BioVersys’ BV500 program.<\/p>\n\n\n\n

Financial Agreement<\/strong>
Under the agreement, BioVersys will receive an upfront payment of CHF 5 million (USD 6.3 million), along with near-term research funding. If Shionogi exercises its option, BioVersys could receive up to CHF 479 million in regulatory and commercial milestone payments, plus royalties on future product sales.<\/p>\n\n\n\n

BV500 Program Highlights<\/strong>
The BV500 program is derived from BioVersys’ proprietary ansamycin chemistry platform, which has enabled the identification of multiple lead compounds with broad-spectrum anti-NTM activity (in vitro and in vivo), high oral bioavailability, and no cross-resistance. These compounds target diseases caused by Mycobacterium avium complex (MAC) and Mycobacterium abscessus (MAB), including pulmonary infections. NTM lung disease requires prolonged treatment with existing therapies that often have severe side effects and limited efficacy, particularly for MAB infections, which carry a mortality rate as high as 50%.<\/p>\n\n\n\n

Clinical and Financial Support<\/strong>
BioVersys noted that its most advanced candidate, BV100, is expected to enter Phase III trials this year. Additionally, the BV500 program has received funding support from the EU’s RespiriNTM and CF AMR Syndicate initiatives.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Swiss biopharma BioVersys AG (SWX: BIOV) announced a research and exclusive license option agreement with…<\/p>\n","protected":false},"author":1,"featured_media":36701,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4201,423,4202,2673],"class_list":["post-36697","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-bioversys","tag-shionogi","tag-swx-biov","tag-tyo-4507"],"yoast_head":"\nBioVersys Partners with Shionogi to Advance BV500 for Non-Tuberculous Mycobacterial Infections - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Swiss biopharma BioVersys AG (SWX: BIOV) announced a research and exclusive license option agreement with Japan-based Shionogi & Co., Ltd. (TYO: 4507) to jointly advance novel ansamycin-class molecules for treating non-tuberculous mycobacterial (NTM) infections. The collaboration is based on BioVersys' BV500 program.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=36697\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioVersys Partners with Shionogi to Advance BV500 for Non-Tuberculous Mycobacterial Infections\" \/>\n<meta property=\"og:description\" content=\"Swiss biopharma BioVersys AG (SWX: BIOV) announced a research and exclusive license option agreement with Japan-based Shionogi & Co., Ltd. (TYO: 4507) to jointly advance novel ansamycin-class molecules for treating non-tuberculous mycobacterial (NTM) infections. The collaboration is based on BioVersys' BV500 program.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=36697\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-04T08:30:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0409.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36697#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36697\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BioVersys Partners with Shionogi to Advance BV500 for Non-Tuberculous Mycobacterial Infections\",\"datePublished\":\"2025-07-04T08:30:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36697\"},\"wordCount\":225,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36697#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0409.webp\",\"keywords\":[\"BioVersys\",\"Shionogi\",\"SWX: BIOV\",\"TYO: 4507\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36697#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36697\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=36697\",\"name\":\"BioVersys Partners with Shionogi to Advance BV500 for Non-Tuberculous Mycobacterial Infections - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36697#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36697#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0409.webp\",\"datePublished\":\"2025-07-04T08:30:11+00:00\",\"description\":\"Swiss biopharma BioVersys AG (SWX: BIOV) announced a research and exclusive license option agreement with Japan-based Shionogi & Co., Ltd. (TYO: 4507) to jointly advance novel ansamycin-class molecules for treating non-tuberculous mycobacterial (NTM) infections. The collaboration is based on BioVersys' BV500 program.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36697#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36697\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36697#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0409.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0409.webp\",\"width\":1080,\"height\":608,\"caption\":\"BioVersys Partners with Shionogi to Advance BV500 for Non-Tuberculous Mycobacterial Infections\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36697#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioVersys Partners with Shionogi to Advance BV500 for Non-Tuberculous Mycobacterial Infections\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BioVersys Partners with Shionogi to Advance BV500 for Non-Tuberculous Mycobacterial Infections - Insight, China's Pharmaceutical Industry","description":"Swiss biopharma BioVersys AG (SWX: BIOV) announced a research and exclusive license option agreement with Japan-based Shionogi & Co., Ltd. (TYO: 4507) to jointly advance novel ansamycin-class molecules for treating non-tuberculous mycobacterial (NTM) infections. The collaboration is based on BioVersys' BV500 program.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=36697","og_locale":"en_US","og_type":"article","og_title":"BioVersys Partners with Shionogi to Advance BV500 for Non-Tuberculous Mycobacterial Infections","og_description":"Swiss biopharma BioVersys AG (SWX: BIOV) announced a research and exclusive license option agreement with Japan-based Shionogi & Co., Ltd. (TYO: 4507) to jointly advance novel ansamycin-class molecules for treating non-tuberculous mycobacterial (NTM) infections. The collaboration is based on BioVersys' BV500 program.","og_url":"https:\/\/flcube.com\/?p=36697","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-04T08:30:11+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0409.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=36697#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=36697"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BioVersys Partners with Shionogi to Advance BV500 for Non-Tuberculous Mycobacterial Infections","datePublished":"2025-07-04T08:30:11+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=36697"},"wordCount":225,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=36697#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0409.webp","keywords":["BioVersys","Shionogi","SWX: BIOV","TYO: 4507"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=36697#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=36697","url":"https:\/\/flcube.com\/?p=36697","name":"BioVersys Partners with Shionogi to Advance BV500 for Non-Tuberculous Mycobacterial Infections - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=36697#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=36697#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0409.webp","datePublished":"2025-07-04T08:30:11+00:00","description":"Swiss biopharma BioVersys AG (SWX: BIOV) announced a research and exclusive license option agreement with Japan-based Shionogi & Co., Ltd. (TYO: 4507) to jointly advance novel ansamycin-class molecules for treating non-tuberculous mycobacterial (NTM) infections. The collaboration is based on BioVersys' BV500 program.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=36697#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=36697"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=36697#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0409.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0409.webp","width":1080,"height":608,"caption":"BioVersys Partners with Shionogi to Advance BV500 for Non-Tuberculous Mycobacterial Infections"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=36697#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BioVersys Partners with Shionogi to Advance BV500 for Non-Tuberculous Mycobacterial Infections"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0409.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36697","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36697"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36697\/revisions"}],"predecessor-version":[{"id":36700,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36697\/revisions\/36700"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36701"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36697"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36697"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36697"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}